more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$831.54 USD

+34.09 (4.27%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $832.66 +1.12 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

Top 19% (47 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Research for LLY

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Sales: Emgality (Galcanezumab...		678	651	577	363	163
Net Sales: Diabetes Total [$M]		19,668	14,465	13,188	11,834	11,132
Net Sales: Neuroscience: Other Ne...		227	125	95	--	--
Net Sales: Oncology: Tyvyt [$M]		393	293	418	--	--
Net Sales: Oncology: Other Oncolo...		613	424	--	--	--
Net Sales: Other - Other - Total ...		1,122	3,520	--	--	--
Net Sales: Diabetes: Mounjaro -To...		5,163	483	--	--	--
Net Sales: Zepbound [$M]	--	176	0	--	--	--
Net Sales: Neurosciences [$M]		2,879	1,546	1,899	1,831	1,723
Net Sales: Oncology [$M] [$M]		6,658	5,666	5,741	5,319	4,614
Net Sales: Other pharmaceuticals ...		1,122	3,520	4,130	3,093	3,057
Net Sales: Cialis [$M] [$M]		381	587	718	607	891
Net Sales: Erbitux [$M] [$M]		597	567	548	536	543
Net Sales: Forteo [$M] [$M]		533	613	802	1,046	1,405
Net Sales: Trulicity (Dulaglutide...		7,133	7,440	6,472	5,068	4,128
Net Sales: Humalog [$M] [$M]		1,663	2,061	2,453	2,626	2,821
Net Sales: Taltz (Ixekizumab / LY...		2,760	2,482	2,213	1,789	1,366
Net Sales: Immunology [$M]		3,798	3,345	3,361	2,462	1,793
Net Sales: Jardiance (Empaglifloz...		2,745	2,066	1,491	1,154	944
Net Sales: Verzenio- Total [$M]		3,863	2,484	1,350	913	580
Net Sales: Humulin [$M] [$M]		852	1,019	1,223	1,260	1,290
Net Sales: Olumiant/Baricitinib (...		923	831	1,115	639	427
Net Sales: Cyramza (Ramucirumab /...		975	971	1,033	1,033	925
Net Sales: Basaglar (LY2963016 / ...		728	760	893	1,124	1,113
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Sales: Cyramza (Ramucirumab /...		402	351	358	382	335
Net Sales: Cyramza (Ramucirumab /...		572	620	675	651	79
Net Sales: Trulicity (Dulaglutide...		5,433	5,689	4,914	4	3,155
Net Sales: Trulicity (Dulaglutide...		1,699	1,751	1,558	1	232
Net Sales: Jardiance (Empaglifloz...		1,600	1,195	807	621	566
Net Sales: Jardiance (Empaglifloz...		1,144	872	684	533	139
Net Sales: Olumiant/Baricitinib (...		226	148	324	64	42
Net Sales: Olumiant/Baricitinib (...		697	682	791	49	28
Net Sales: Taltz (Ixekizumab / LY...		1,832	1,725	1,542	1	1,017
Net Sales: Taltz (Ixekizumab / LY...		928	757	670	500	64
Net Sales: Verzenio- US [$M]		2,509	1,653	835	618	125
Net Sales: Emgality (Galcanezumab...		482	463	435	618	8
Net Sales: Emgality (Galcanezumab...		196	188	143	37	8
Net Sales: Verzenio- ROW [$M]		1,354	830	515	294	125
Net Sales: Diabetes- United State...		14,781	9,911	8,719	--	--
Net Sales: Diabetes- Outside U.S ...	--	4,887	4,554	4,469	--	--
Net Sales: Oncology- United State...		3,797	3,218	--	2,792	2,609
Net Sales: Oncology- Outside U.S ...		2,861	2,448	--	2,527	2,006
Net Sales: Immunology- United Sta...		2,058	1,893	1,882	1,372	1,059
Net Sales: Immunology- Outside U....		1,740	1,452	1,479	1,090	734
Net Sales: Neuroscience- United S...		696	612	615	487	357
Net Sales: Neuroscience- Outside ...		2,183	934	1,284	1,344	1,366
Net Sales: Other pharmaceuticals:...		459	2,556	547	1,668	1,169
Net Sales: Other pharmaceuticals:...		663	964	781	1,424	1,888
Net Sales: Oncology: Tyvyt - Outs...		393	293	418	--	--
Net Sales: Oncology: Erbitux - U....		529	500	361	--	--
Net Sales: Oncology: Erbitux - Ou...		68	66	47	--	--
Net Sales: Oncology: Other Oncolo...		34	170	120	--	--
Net Sales: Oncology: Other Oncolo...		147	254	211	--	--
Revenue to unaffiliated customers...		--	--	7,708	--	--
Net Sales: Other: Other -U.S. [$M...		459	2,556	--	--	--
Net Sales: Other: Other -Outside ...		663	964	--	--	--
Net Sales: Diabetes: Mounjaro -U....		4,834	367	--	--	--
Net Sales: Diabetes: Mounjaro -Ou...		329	116	--	--	--
Net Sales: Other Neuroscience: Ot...		134	119	102	--	--
Net Sales: Other Neuroscience- Ou...		371	439	208	--	--
Net Sales: US-Cialis [$M] [$M]		26	35	11	--	232
Net Sales: US-Forteo [$M] [$M]		336	367	442	510	646
Net Sales: International-Cialis [...		678	651	708	--	659
Net Sales: International-Forteo [...		198	246	360	536	759
Geographic Revenue: China [$M]		1,540	1,453	1,661	1,117	939
Geographic Revenue: United States...		21,791	18,190	16,811	14,229	12,723
Geographic Revenue: Europe [$M]		6,175	4,299	4,777	4,188	3,765
Geographic Revenue: Japan [$M]		1,673	1,747	2,367	2,583	2,548
Geographic Revenue: Other foreign...		2,946	2,852	2,702	2,423	2,345
Net Sales: Basaglar (LY2963016 / ...		443	471	588	842	876
Net Sales: Basaglar (LY2963016 / ...		285	290	304	282	65
Net Sales: US-Humalog [$M] [$M]		863	1,192	1,321	1	1,670
Net Sales: International-Humalog ...		800	869	1,132	1	1,151
Net Sales: US-Humulin [$M] [$M]		610	730	833	866	880
Net Sales: International-Humulin ...		242	289	390	393	410

Revenue - Line of Business Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Net Sales: Emgality (Galcanezumab...		203	192	226	58	169
Net Sales: Diabetes Total [$M]		7,407	7,515	5,493	5,746	4,720
Net Sales: Neuroscience: Other Ne...		96	91	101	68	48
Net Sales: Oncology: Tyvyt [$M]		150	123	117	114	115
Net Sales: Oncology: Other Oncolo...		52	53	49	47	48
Net Sales: Other - Other - Total ...		31	31	22	34	43
Net Sales: Diabetes: Mounjaro -To...	--	96	3,091	1,807	2,206	1,409
Net Sales: Zepbound [$M]		1,258	1,243	517	176	--
Net Sales: Neurosciences [$M]		352	340	389	363	1,768
Net Sales: Oncology [$M] [$M]		2,232	2,159	1,810	1,884	1,747
Net Sales: Other pharmaceuticals ...		263	208	242	256	276
Net Sales: Cialis [$M] [$M]		92	88	139	79	87
Net Sales: Erbitux [$M] [$M]		152	156	145	150	154
Net Sales: Forteo [$M] [$M]		118	70	61	116	146
Net Sales: Trulicity (Dulaglutide...		1,301	1,246	1,456	1,669	1,674
Net Sales: Humalog [$M] [$M]		535	632	539	367	395
Net Sales: Taltz (Ixekizumab / LY...		880	825	604	785	744
Net Sales: Immunology [$M]		1,186	1,082	834	1,104	987
Net Sales: Jardiance (Empaglifloz...		686	770	687	798	701
Net Sales: Verzenio- Total [$M]		1,369	1,332	1,050	1,145	1,040
Net Sales: Humulin [$M] [$M]		207	224	206	188	207
Net Sales: Olumiant/Baricitinib (...		251	228	217	244	231
Net Sales: Cyramza (Ramucirumab /...		236	249	230	254	224
Net Sales: Basaglar (LY2963016 / ...		162	181	158	185	180
Revenue - Geographic Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Net Sales: Cyramza (Ramucirumab /...		107	116	107	99	88
Net Sales: Cyramza (Ramucirumab /...		129	133	123	155	136
Net Sales: Trulicity (Dulaglutide...		935	877	1,082	1,256	1,259
Net Sales: Trulicity (Dulaglutide...		366	369	374	414	415
Net Sales: Jardiance (Empaglifloz...		336	429	368	469	416
Net Sales: Jardiance (Empaglifloz...		351	341	318	329	285
Net Sales: Olumiant/Baricitinib (...	--	69	45	46	67	66
Net Sales: Olumiant/Baricitinib (...		182	183	171	177	166
Net Sales: Taltz (Ixekizumab / LY...		600	539	347	538	509
Net Sales: Taltz (Ixekizumab / LY...		279	285	257	247	235
Net Sales: Verzenio- US [$M]		879	861	638	775	685
Net Sales: Emgality (Galcanezumab...		141	138	125	128	127
Net Sales: Emgality (Galcanezumab...		62	54	101	186	42
Net Sales: Verzenio- ROW [$M]		490	471	412	371	356
Net Sales: Diabetes- United State...		5,517	5,716	4,090	4,464	3,460
Net Sales: Diabetes- Outside U.S ...		1,890	1,799	1,403	1,282	1,260
Net Sales: Oncology- United State...		1,294	1,275	998	1,107	1,002
Net Sales: Oncology- Outside U.S ...		938	884	812	777	746
Net Sales: Immunology- United Sta...		694	600	397	605	575
Net Sales: Immunology- Outside U....		492	483	437	499	412
Net Sales: Neuroscience- United S...		201	192	163	183	207
Net Sales: Neuroscience- Outside ...		151	148	226	180	1,561
Net Sales: Other pharmaceuticals:...		107	52	46	96	124
Net Sales: Other pharmaceuticals:...		156	155	196	161	152
Net Sales: Oncology: Tyvyt - Outs...		150	123	117	114	115
Net Sales: Oncology: Erbitux - U....		133	143	132	131	134
Net Sales: Oncology: Erbitux - Ou...		19	13	13	20	20
Net Sales: Oncology: Other Oncolo...		9	10	12	30	16
Net Sales: Oncology: Other Oncolo...		44	43	37	38	32
Revenue to unaffiliated customers...		3,626	3,468	3,074	--	4,131
Net Sales: Other: Other -U.S. [$M...		16	4	8	7	18
Net Sales: Other: Other -Outside ...		15	27	15	27	25
Net Sales: Diabetes: Mounjaro -U....		2,385	2,414	1,520	2,105	1,277
Net Sales: Diabetes: Mounjaro -Ou...		728	677	286	101	132
Net Sales: Other Neuroscience: Ot...		45	41	28	30	31
Net Sales: Other Neuroscience- Ou...		50	50	73	38	87
Net Sales: US-Cialis [$M] [$M]		4	8	6	5	5
Net Sales: US-Forteo [$M] [$M]		72	32	22	66	101
Net Sales: International-Cialis [...		87	80	133	74	82
Net Sales: International-Forteo [...		46	39	40	50	45
Geographic Revenue: China [$M]		460	395	376	--	391
Geographic Revenue: United States...		7,814	7,835	5,694	6,455	5,368
Geographic Revenue: Europe [$M]		1,628	1,404	1,441	--	2,569
Geographic Revenue: Japan [$M]		429	463	364	--	391
Geographic Revenue: Other foreign...		1,108	1,206	893	2,898	780
Net Sales: Basaglar (LY2963016 / ...		86	105	83	113	111
Net Sales: Basaglar (LY2963016 / ...		76	76	74	72	68
Net Sales: US-Humalog [$M] [$M]		324	435	338	168	194
Net Sales: International-Humalog ...		211	197	200	199	201
Net Sales: US-Humulin [$M] [$M]		150	169	153	122	146
Net Sales: International-Humulin ...		57	54	53	67	61

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators